Categories: EngineeringFastPlatformTechnology
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.
Investors 2
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.04.2025 | Series C | $90M | - |
| 10.05.2024 | Series B | $105M | - |
Mentions in press and media 6
| Date | Title | Description |
| 21.04.2025 | Attovia Therapeutics: $90 Million (Series C) Raised For Developing Treatments For Immune-Mediated Diseases | Attovia Therapeutics, a privately held, clinical-stage biopharma company developing treatments for immune-mediated diseases with high unmet patient need, announced the closing of a $90 million Series C funding. Deep Track Capital led this f... |
| 16.04.2025 | Attovia Therapeutics Secures $90 Million to Revolutionize Treatments for Immune-Mediated Diseases | In the world of biopharmaceuticals, funding is the lifeblood that fuels innovation. Attovia Therapeutics, a clinical-stage company based in San Carlos, California, has just secured a significant boost with a $90 million Series C financing r... |
| 16.04.2025 | Attovia Therapeutics Raises $90M in Series C Financing | Attovia Therapeutics, a San Carlos, CA-based clinical-stage biopharma company, raised $90M in Series C funding.
The round was led by Deep Track Capital with participation from new investors including Vida Ventures, Sanofi Ventures, and Mira... |
| 15.04.2025 | Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept | Series C round led by Deep Track Capital with participation from additional new and existing investors
Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and multipl... |
| 10.05.2024 | Attovia Therapeutics Raises $105M in Series B Financing | Attovia Therapeutics, a Fremont, CA-based developer of a pipeline of biotherapeutics with an initial focus on immune-mediated diseases, raised $105m in Series B financing.
The round, which brought the total amount to $165m, was led by Goldm... |
| - | Attovia Therapeutics | “Harnessing ATTOBODY® technology to bring treatments to patients where none exist or where current solutions fall short.” |
Reviews 0
